RELPAX (eletriptan hydrobromide) tablets contain eletriptan hydrobromide, which is a selective 5-hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist.
RELPAX is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use:
- Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with RELPAX, reconsider the diagnosis of migraine before RELPAX is administered to treat any subsequent attacks.
- RELPAX is not intended for the prevention of migraine attacks.
- Safety and effectiveness of RELPAX have not been established for cluster headache.
Media Articles Related to Relpax (Eletriptan)
Six New Studies Illuminate Causes and Comorbidities in Migraine
Source: Medscape NeurologyHeadlines [2016.08.26]
Dr Christoph Diener surveys new data on the causes, treatment, and comorbidities of migraine.
'Tentative' FDA Nod to Trokendi XR for Migraine Prevention
Source: Medscape NeurologyHeadlines [2016.08.22]
The agency granted tentative approval to expand the label for an extended-release topiramate product, already approved for epilepsy, to include prophylaxis of migraine in adults, pending expiry of pediatric exclusivity in 2017.
Research on an fMRI-Based Neurologic Signature of Physical Pain to be Presented at Upcoming 10th Annual Pain & Migraine Therapeutics Summit
Source: Conferences News From Medical News Today [2016.08.16]
As persistent pain is solely measured by self-report, research is currently being conducted to find objective methods of identifying physical pain in the brain.
10th Annual Pain & Migraine Therapeutics Summit, October 19-20, 2016, Chicago
Source: Conferences News From Medical News Today [2016.08.01]
Centrexion Therapeutics has announced a collaborative agreement with BioXcel to develop and commercialize innovative chronic pain therapeutics.
Migraine: Discovery of new genetic risk variants supports a vascular cause
Source: Headache / Migraine News From Medical News Today [2016.06.25]
Researchers have identified 28 new genetic risk variants for migraine, many of which are located in or near genes related to vascular disease.
Published Studies Related to Relpax (Eletriptan)
Efficacy of eletriptan in triptan-naive patients: results of a combined analysis. [2007.02]
OBJECTIVE: To compare the efficacy and tolerability of eletriptan 20 mg, 40 mg, and 80 mg in triptan-naive patients (who have not previously used triptans) versus triptan-experienced patients (who have previously used triptans)... CONCLUSIONS: These data suggest that eletriptan has comparable efficacy versus placebo among both triptan-naive and triptan-experienced patients.
Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. [2006.03]
Preference is a composite, patient-oriented endpoint incorporating efficacy, tolerability, formulation, and convenience of medications. The objective of this study was to compare patient preference for rizatriptan 10-mg wafer vs... The single most important reason for preference was speed of relief, consistent with results from previous preference studies.
Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. [2005.09]
This double-blind, placebo-controlled study was designed to evaluate the efficacy and tolerability of early treatment of a single migraine attack, when headache pain was mild, with two doses (20 mg and 40 mg) of eletriptan. Patients (N = 613; female 79%; mean age 39 years) meeting International Headache Society criteria for migraine were encouraged, but not required, to utilize early treatment, thus providing an opportunity to assess the relative contribution to efficacy of pain severity and timing of dose...
Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan. [2005.02]
This current randomized, open-label, crossover study evaluated preference for oral eletriptan 80 mg compared with subcutaneous sumatriptan 6 mg (suma-sc) amongst patients (n = 311) meeting IHS criteria for migraine who had recently used suma-sc, and found it well tolerated... The results of this study suggest that eletriptan is a strong alternative option for patients who have been prescribed suma-sc.
No effect of eletriptan administration during the aura phase of migraine. [2004.10]
Migraine aura is a warning sign readily recognized by patients... This study confirms the findings of two studies showing that triptans are ineffective but safe when given during the migraine aura phrase.
Clinical Trials Related to Relpax (Eletriptan)
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine [Completed]
Pharmacokinetics of Two Eletriptan Oral Formulations Given With and Without Water and the Commercial Tablet Formulation Given With Water [Completed]
The study will evaluate whether the blood concentrations of eletriptan administered using
two test formulations of oral disintegrating tablets are comparable to those observed with
the standard commercial tablet.
Prospective Survey of Menstrual Migraine & Prevention With Eletriptan [Completed]
Women are followed prospectively for 3 months, recording headaches, other symptoms, and
menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan
for 3 months.
Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan [Completed]
To determine the tolerability and efficacy of eletriptan in patients who had discontinued
oral sumatriptan due to lack of efficacy or intolerable adverse events (AEs) during previous
clinical treatment (not a controlled trial).
Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine [Completed]
The purpose of this study is to Compare the efficacy of zolmitriptan 5 mg nasal spray vs.
eletriptan 40 mg tablet in the acute treatment of migraine.
To develop and evaluate a set of importance weights for a predefined set of treatment
attributes for migraine suffers using zolmitriptan 5 mg nasal spray vs. eletriptan 40 mg
To contrast the efficacy of zolmitriptan 5 mg nasal spray vs. eletriptan 40 mg tablet at
early time points.
To analyze the patterns of self-reported tolerability of migraine sufferers using
zolmitriptan 5 mg nasal spray vs. eletriptan 40 mg tablet.
Reports of Suspected Relpax (Eletriptan) Side Effects
Drug Ineffective (49),
Feeling Abnormal (17),
Chest Discomfort (13),
Pain in Extremity (9), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 6 ratings/reviews, Relpax has an overall score of 8. The effectiveness score is 8 and the side effect score is 8.33. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
Relpax review by 47 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || migraine relief|
|Dosage & duration:|| || 25mg taken 4x/month for the period of 3 years|
|Other conditions:|| || n/a|
|Other drugs taken:|| || n/a|
|Benefits:|| || migraine pain relieved in 1 - 2 hours and lasted for 24 hours with 1 tablet|
|Side effects:|| || none|
|Comments:|| || 1 tablet at first signs of headache|
Relpax review by 40 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || Migraines|
|Dosage & duration:|| || can't remember (dosage frequency: 1 every 24 hrs as needed for migraine) for the period of once a month|
|Other conditions:|| || n/a|
|Other drugs taken:|| || Pristiq|
|Benefits:|| || It would ease the throbbing feeling associated with a migraine.|
|Side effects:|| || Low blood pressure.|
|Comments:|| || You could feel a marked difference in your blood pressure, that was the only negative side effect. Other than that, it helped calm the pulsating sensation you would get with an intense migraine. Helping you to relax and feel better. |
Relpax review by 39 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Marginally Effective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || migraine headaches|
|Dosage & duration:|| || .5 (dosage frequency: 2 times per day) for the period of 3 days|
|Other conditions:|| || none|
|Other drugs taken:|| || birth control|
|Benefits:|| || The medication took almost thirty minutes to kick in. Once the medication started to take affect, I began to develop a tingling sensation in my left hand and later my right hand. I also noticed my hands were very shaky after the medication was in my system for at least an hour.|
|Side effects:|| || The medication took almost thirty minutes to kick in. Once the medication started to take affect, I began to develop a tingling sensation in my left hand and later my right hand. I also noticed my hands were very shaky after the medication was in my system for at least an hour.|
|Comments:|| || Once a migraine is formulating, one pill is to be taken. The medication took almost thirty minutes to kick in. Once the medication started to take affect, I began to develop a tingling sensation in my left hand and later my right hand. I also noticed my hands were very shaky after the medication was in my system for at least an hour.|
Page last updated: 2016-08-26